drugset / Trial / NCT03031262
Efficacy and Safety of Chidamide in CBF Leukemia
Phase 1/2
Active not recruiting
250 enrolled
Institute of Hematology & Blood Diseases Hospital, China
RandomizedParallel-groupOpen-labelTreatment
Summary
In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus chidamide.The safety and efficacy of chidamide is evaluated.
Timeline
- Start
- 2017-02-08
- Primary completion
- 2025-04-10
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | 20 mg | — |
| Background | Cytarabine | Small molecule | 3000 mg/m2 | — |